Last reviewed · How we verify

SER-109 — Competitive Intelligence Brief

SER-109 (SER-109) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microbiome therapeutic. Area: Infectious Disease / Gastroenterology.

phase 3 Microbiome therapeutic Infectious Disease / Gastroenterology Biologic Live · refreshed every 30 min

Target snapshot

SER-109 (SER-109) — Seres Therapeutics, Inc.. SER-109 is a spore-based microbiome therapeutic that restores healthy gut bacterial composition to prevent recurrent Clostridioides difficile infection.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SER-109 TARGET SER-109 Seres Therapeutics, Inc. phase 3 Microbiome therapeutic
Fecal filtrate transplantation Fecal filtrate transplantation University of Pecs phase 3 Microbiome therapeutic / Fecal derivative

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Microbiome therapeutic class)

  1. Seres Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SER-109 — Competitive Intelligence Brief. https://druglandscape.com/ci/ser-109. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: